Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Search Close Search
Search Close Search
Page Menu

Terence R. Flotte, MD

Celia and Isaac Haidak Professor, Dean of School of Medicine
Provost and Executive Deputy Chancellor
"This is an exciting time to be pursuing a career in medicine and applying to the University of Massachusetts Medical School"

 

About the Dean 

Terence R. Flotte, MD

Since joining UMass Medical School in 2007, Dean Flotte has led numerous successful initiatives elevating the academic stature of the institution, including establishing the Department of Quantitative Health Sciences; establishment of neurosurgery, urology and ophthalmology as academic departments; recruitment of numerous department chairs; and development of the Advanced Therapeutics Cluster. During Flotte’s time as dean of the School of Medicine, class size has increased from 103 to 162; a revised curriculum has been developed and implemented including “Learning Communities” guided by faculty mentors. in 2016, the medical school opened its first regional campus in Springfield, Mass. The research enterprise of the institution has grown to more than $280 million and a new 512,000-square-foot multiuse facility was built to accommodate the growing clinical and translational research laboratories as well as provide a new educational home for faculty and students.

An internationally known pioneer in human gene therapy, Flotte is currently investigating the use of gene therapy for genetic diseases, including alpha-1 antitrypsin deficiency and Tay-Sachs disease. In 1995, he led the team at Johns Hopkins that became the first to use the apparently harmless adeno-associated virus, or AAV, as a vehicle to deliver corrective genes to targeted sites in the body, including the damaged airways of adults with cystic fibrosis. He is the author of more than 250 scholarly papers and his research has been funded by the National Institutes of Health and the Alpha One Foundation. Since 2015, Flotte has also been editor-in-chief of gene therapy’s oldest journal family, Human Gene Therapy.Button - Learn More

  • Innovative neurosurgical technique used in Tay-Sachs gene therapy clinical trial
    Mar 3, 2021

    Innovative neurosurgical technique used in Tay-Sachs gene therapy clinical trial

    Oguz Cataltepe, MD, describes the innovative neurosurgical procedure used to treat patients in the new clinical trial for a gene therapy targeting infantile Tay-Sachs and Sandhoff diseases.

    Read more
  • First patient dosed in clinical trial of gene therapy for Tay-Sachs and Sandhoff diseases
    Feb 3, 2021

    First patient dosed in clinical trial of gene therapy for Tay-Sachs and Sandhoff diseases

    Sio Gene Therapies announced that the first patient with infantile Tay-Sachs disease has been dosed in a Phase I/II trial evaluating AXO-AAV-GM2, an investigational gene therapy for the treatment of GM2 gangliosidosis, which causes Tay-Sachs and Sandhoff diseases. Miguel Sena-Esteves, PhD, is a principal scientist of the research program at UMMS.

    Read more
  • FDA clears IND application for Tay-Sachs gene therapy
    Nov 9, 2020

    FDA clears IND application for Tay-Sachs gene therapy

    Axovant Gene Therapies, a clinical-stage company developing innovative gene therapies based on UMass Medical School research discoveries, has announced that the FDA has lifted its clinical hold and cleared Axovant’s Investigational New Drug application to initiate a registrational study of gene therapy to treat patients with Tay-Sachs disease and Sandhoff disease.

    Read more
  • Nine-story biomedical research and education facility to be built at UMass Medical School
    Oct 20, 2020

    Nine-story biomedical research and education facility to be built at UMass Medical School

    UMass Medical School has received approval from the University of Massachusetts Board of Trustees to build a nine-story biomedical research and education facility on the Worcester campus to support laboratory research growth and the educational enterprise.

    Read more
  • UMass Medical School taking a stand in support of positive change
    Jun 12, 2020

    UMass Medical School taking a stand in support of positive change

    In a memo to the UMass Medical School community, Chancellor Michael F. Collins and Dean Terence R. Flotte say racism is a public health crisis and outline changes underway at UMMS.

    Read more
  • WBUR reports on early results for gene therapy trial for two young children with Tay-Sachs disease
    Oct 25, 2019

    WBUR reports on early results for gene therapy trial for two young children with Tay-Sachs disease

    Two young children with Tay-Sachs disease were treated safely at UMass Memorial Medical Center with a gene therapy developed at UMass Medical School and, in one case, the child’s condition has stabilized, according to an interview published by WBUR with Terence R. Flotte, MD.

    Read more
  • First evidence of clinical stabilization in Tay-Sachs presented at European Society of Gene & Cell Therapy Congress
    Oct 23, 2019

    First evidence of clinical stabilization in Tay-Sachs presented at European Society of Gene & Cell Therapy Congress

    Preliminary data from an expanded access study of an investigational gene therapy in two patients with infantile Tay-Sachs disease indicates the potential to modify the rate of disease progression, according to a recent report presented in Barcelona by Terence R. Flotte, MD.

    Read more
  • Chancellor Collins, colleagues propose reforms to medical residency matching program
    Mar 25, 2019

    Chancellor Collins, colleagues propose reforms to medical residency matching program

    Reforms are needed to ensure the integrity of the medical residency program selection process, according to commentary in the journal Academic Medicine by Chancellor Michael F. Collins and colleagues at UMass Medical School.

    Read more
  • Blu Genes Foundation gives UMMS $1.4M to bring Tay-Sachs gene therapy to clinical trial
    Nov 6, 2018

    Blu Genes Foundation gives UMMS $1.4M to bring Tay-Sachs gene therapy to clinical trial

    The Toronto-based Blu Genes Foundation, which is dedicated to developing gene therapies for rare disease, has given $1.4 million to UMass Medical School to advance a Phase I/II clinical trial for Tay-Sachs. Miguel Sena-Esteves, PhD, Terence Flotte, MD, Heather Gray-Edwards, PhD, DVM, and colleagues at  Auburn University are leading the research.

    Read more
  • AAMC: No tolerance for sexual harassment in academic medicine
    Nov 14, 2017

    AAMC: No tolerance for sexual harassment in academic medicine

    Dean Terence R. Flotte served as senior author on a call to action published in Academic Medicine, titled, “It is time for zero tolerance for sexual harassment in academic medicine.”

    Read more
More news